|
 |
RaloxifeneThis page contains recent news articles, when available, and an overview of Raloxifene but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: Raloxifene (when available) Raloxifene, a selective estrogen receptor modulator (SERM) of the benzothiophene class, is similar to tamoxifen in that it produces estrogen-like effects on bone and lipid metabolism, while antagonizing the effects of estrogen on mammary tissue. Raloxifene decreases bone resorption, increases bone mineral density (BMD) and decreases incidence of fractures. Raloxifene is used in the prevention of postmenopausal osteoporosis and breast cancer. For the prevention of osteoporosis in post-menopausal women Mechanism Of Action: Raloxifene binds to estrogen receptors, resulting in differential expression of multiple estrogen-regulated genes in different tissues. Raloxifene produces estrogen-like effects on bone, reducing resorption of bone and increasing bone mineral density in postmenopausal women. Raloxifene also antagonizes the effects of estrogen on mammary tissue and blocks uterotrophic responses to estrogen. News Articles on Raloxifene Medications decrease risk of breast cancer, studies find - Aug 26, 2009 Then, in a study designed to evaluate the benefit of a drug similar to tamoxifen called raloxifene with regard to osteoporosis, researchers noted that the St. Louis Post-Dispatch News briefing: 27 August 2009 - Aug 26, 2009 The company, headquartered in Indianapolis, Indiana, had hoped arzoxifene would be a successor to its blockbuster osteoporosis treatment raloxifene (Evista) Nature.com (subscription) Arzoxifene: Not the Road to Big Profits? - Aug 24, 2009 Eli Lilly announced some bad news last week when they dropped arzoxifene, a once-promising osteoporosis treatment (and successor to Evista (raloxifene), Corante FDA committee vote: Denosumab benefits outweigh risks for ... - Aug 17, 2009 Either raloxifene or teriparatide may not be suitable for the patient with moderate osteoporosis or moderate fracture risk. Ortho SuperSite Study setback presents ominous signs for key osteoporosis drug class - Aug 20, 2009 Eli Lilly had hoped to launch arzoxifene as a follow-on product to its class leading Evista (raloxifene) prior to patent expiry in 2012. Trading Markets (press release) Good news, bad news for osteoporosis - Aug 14, 2009 Raloxifene (Evista, Eli Lilly) is available as a daily oral preparation while estrogen is available as an oral or transdermal product. Endocrine Today Denosumab for Prevention of Fractures in Postmenopausal Women with ... - Aug 11, 2009 Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis. Arch Intern Med 2002;162:1140-1143. New England Journal of Medicine (subscription) EVISTA עלולה להגביר ×?ת הסיכון לשבץ מוחי ×§×˜×œ× ×™ - Aug 16, 2009 EVISTA ×?ו בשמה ×”×’× ×¨×™ RALOXIFENE מיועדת לטיפול ×‘×ž× ×™×¢×ª שברי חוליות עקב ×?וסט×?ופורוזיס, מלבד ×”×¤×•×˜× ×¦×™×?ל הטיפול ×‘×ž× ×™×¢×ª סרטן שד. מחקר המתפרס×? ב - AMERICAN JOURNAL מרכז הרופאים המומחים $7.5 million grant to aid breast cancer study - 14 Jul 2009 The human part of the study includes five experimental arms involving different dosages of Raloxifene (Evista), an antiestrogen; Lovaza, a prescription PennLive.com Product Market Definition in the Pharmaceutical Sector: The Effect ... - 14 Jul 2009 ...the same or similar ways and are considered alternatives by prescribers (prima facie, Anastrozole and Raloxifene belong to the same group as Tamoxifen). Linex Legal (subscription) Utility under Canadian Patent Law and the Doctrine of Sound Prediction - Jun 21, 2009 2101356 ('356 patent) is directed to the use of a group of compounds (including raloxifene) in the treatment or prevention of osteoporosis and for Patent Docs Management of Osteoporosis Among Home Health and Long-term Care ... - Jun 18, 2009 Cost-effectiveness of osteoporosis screening and treatment with hormone replacement therapy, raloxifene, or alendronate. Med Decis Making 2006;26:194-206. Medscape Ariad's NFB patent claims shot down on appeal - Jun 19, 2009 The dispute centered on Lilly's osteoporosis drug Evista (raloxifene) and sepsis drug Xigris (activated protein C), but the case's implications extended far Nature.com (subscription) What Is Osteoporosis? What Causes Osteoporosis? - Jun 28, 2009 Raloxifene is an example of this type of drug. Patients who have a history of blood clots should not take this medication. A common side effect is hot Medical News Today V. Craig Jordan, Internationally Renowned Breast Cancer Scientist ... - 20 Apr 2009 A related drug and SERM, raloxifene, also came from Jordan's laboratory. Raloxifene is used both for the prevention of breast cancer and osteoporosis. PR Newswire (press release) Lilly Reports Strong First-Quarter 2009 Results - 20 Apr 2009 Lilly) Efient(R) (prasugrel, Lilly) Erbitux(R) (cetuximab, ImClone Systems, Lilly) Evista(R) (raloxifene hydrochloride, Lilly) Forteo(R) (teriparatide American Chronicle Breast density measurements can be cancer prevention tool - Apr 5, 2009 ...risk by taking preventive drugs like tamoxifen and raloxifene, said Cummings, who recommends density readings be added to a woman's regular mammogram. Chicago Daily Herald Lilly wins appeal in Ariad patent litigation - Apr 3, 2009 Evista or raloxifene hydrochloride is one of Eli Lilly's best-selling drugs and is intended to reduce both the risk of spinal fractures due to osteoporosis International Business Times Bệnh loãng xÆ°Æ¡ng - Apr 5, 2009 Ngoà i ra, các dược phẩm nhÆ° Raloxifene, calcitonin, estrogen, kÃch thÃch tố tuyến cáºn giáp cÅ©ng được dùng để trị loãng xÆ°Æ¡ng. Phòng tránh loãng xÆ°Æ¡ng đã Người Việt هشاشة العظام لدى الرجال.. الوقاية والعلاج - Apr 7, 2009 ومع ذلك Ù?إن «رالوكسيÙ?ين« raloxifene الذي يعمل على الاستروجين يظل آمنا ÙˆÙ?عالا للنساء بعد سن اليأس. إلا أن كلا الدواءين المذكورين آنÙ?ا ليسا Ù…Ù?يدا للرجال. دنيا الوطن Questioning the Accuracy of a Recent Review of Osteoporosis ... - Mar 16, 2009 Specifically regarding the inclusion of data from various studies pertaining to the relationship between raloxifene and breast cancer, we did include data Annals of Internal Medicine Lilly Granted Temporary Restraining Order to Halt Launch of ... - Mar 9, 2009 Also, the company cannot predict whether generic raloxifene will be marketed prior to the resolution of this litigation. Other risk factors that may affect PR Newswire (press release) Older women with the metabolic syndrome had a 66 percent increase ... - Mar 11, 2009 The 4895 study participants were enrollees in the Multiple Outcomes of Raloxifene Evaluation trial, which examined the effect of the osteoporosis drug Media Newswire (press release) Federal Circuit Affirms Extension of Stay Against Teva's Generic ... - Feb 25, 2009 6458811; 6797719; and 6894064--covering raloxifene particle size and formulations. On July 8, 2008, Teva amended its ANDA to include a new particle-size Seeking Alpha Metabolic Syndrome Linked to Cognitive Impairment - Mar 9, 2009 To assess the association, the researchers conducted a subgroup analysis of the Multiple Outcomes of Raloxifene Evaluation (MORE) study of 4895 older women MedPage Today Eli Lilly & Co. v. Teva Pharms. USA, Inc. - Mar 5, 2009 Teva filed an ANDA with the FDA in early 2006, seeking approval to manufacture and market generic raloxifene. . . . Lilly sued Teva on June 29, 2006, Linex Legal Postmenopausal women should be screened for breast cancer by risk ... - Mar 16, 2009 The risk for estrogen receptor–positive invasive breast cancer and invasive breast cancer overall decreased with tamoxifen and raloxifene (Evista, Lilly). Endocrine Today Systematic Estimation Of Breast Cancer Risk Appears Justified In ... - Mar 10, 2009 A meta-analysis supported the efficacy of either tamoxifen or raloxifene for primary prevention of breast cancer. Finally, a systematic review and Science Daily (press release) Breast Cancer Risk Assessment Warranted in Older Women - Mar 11, 2009 ..."We also found that both tamoxifen and raloxifene reduced the risk of invasive (estrogen receptor-positive) breast cancer," Dr. Cummings and associates Cancerpage.com Lasofoxifene Decreases Risk of Breast Cancer, Fractures Among ... - Mar 13, 2009 ...this study," said Dr. Powles after outlining the risks and benefits of first- and second-generation SERMs (tamoxifen and raloxifene) with lasofoxifene. DG News Aciphex cause of osteoporosis? Slowing bone loss - Mar 3, 2009 Raloxifene (Evista) and estrogen therapy also increase bone density and reduce fracture risk, but their side effects and lower effectiveness (compared with Newsday Five breakthroughs already at Scripps Florida - Feb 19, 2009 Tamoxifen and raloxifene are two now on the market, and many more are under study. Assessing how well such drugs will work has been time-consuming and Palm Beach Post Spending the Least Where It Can Do the Most - Mar 2, 2009 Yet even after Lilly received FDA approval for the use of raloxifene to prevent breast cancer in postmenopausal women, “Some people have already come up to Oncology Nursing News Alternatives exist for hormone therapy - Mar 11, 2009 Prescription synthetic estrogen drugs like Premarin and newer drugs like raloxifene and alendronate have been proven to reduce the symptoms of menopause and Little About Gynecomastia Correction – The Cure for Man Boobs - Mar 4, 2009 Drugs such as tamoxifen and raloxifene, which are commonly used to treat breast cancer, may be effective in treating some cases of gynecomastia as well. Best Syndication Drug Repositioning Strategies: Innovative Strategies to Boost ... - Mar 10, 2009 ...successful repositioned drugs such as raloxifene (Evista; Lilly), thalidomide (Thalomid; Celegene), (Exubera;Pfizer/Nektar) have enabled innovative PharmiWeb.com (press release) Osteoporosis Management Reviewed - Feb 3, 2009 For selected patient subgroups, raloxifene, calcitonin, teriparatide, or hormonal therapy may be considered. Raloxifene may be given at doses of 60 mg daily Medscape What's the evidence for raloxifene? - Jan 21, 2009 There's good evidence that raloxifene can lower your chances of breaking a bone in your spine if you are a woman with osteoporosis and have been through the guardian.co.uk, Raloxifene Associated with Thrombosis, Fatal Stroke in ... - Jan 14, 2009 NEW YORK JAN 13, 2009 (Reuters Health) - Treatment with the nonsteroidal selective estrogen receptor modulator raloxifene may heighten the risk of venous Cancerpage.com, Hormone replacement therapy for women having hormone treatments - Jan 21, 2009 Two other drugs, tibolone and raloxifene, may also prevent thinning bones that can lead to osteoporosis. When used on their own (to treat symptoms of the guardian.co.uk, Choosing a drug to treat osteoporosis - Feb 3, 2009 Raloxifene (Evista). This drug can reduce bone loss through an estrogen-like effect. A unique side-effect is that its use is associated with a reduced risk Newsday, NCCN Updates Breast Cancer and Breast Cancer Risk Reduction Guidelines - Feb 3, 2009 For postmenopausal women, raloxifene is listed as equivalent to tamoxifen in reducing the risk of developing invasive breast cancer; however, PR Newswire (press release), Servier takes NICE to court over Protelos guidance - Jan 21, 2009 Strontium ranelate or raloxifene (Lilly's Evista) could be used in limited circumstances for the secondary prevention of fractures in patients who are Scrip World Pharmaceutical News (subscription), To Avoid Osteoporosis, Start Early - Jan 28, 2009 Women can also take raloxifene, which protects bone by slowing bone thinning and causing increased bone thickness. The third big option in medication is U.S. News & World Report, What treatments work for osteoporosis? - Jan 21, 2009 They include raloxifene, teriparatide, strontium ranelate and calcitonin. We don't know what happens to your bones when you stop taking any of these drugs. guardian.co.uk, Lilly posts loss after ImClone charges, major merger ruled out - Jan 30, 2009 The osteoporosis drug Evista (raloxifene), which is also approved for the prevention of breast cancer for certain postmenopausal women, had revenues of Pharma Times, Ringtone verizon - Jan 17, 2009 Gift pregnancy ringtone verizon raloxifene mechanism icos service miami. Working ringtone verizon need discontinued ringtone verizon diet buy farmacia Griggs County Courier, Generic vicodin identification - Jan 17, 2009 Gift pregnancy generic vicodin identification raloxifene mechanism icos service miami. Working generic vicodin identification need discontinued generic Griggs County Courier, Pfizer Receives FDA Complete Response Letter for Lasofoxifene - Jan 16, 2009 Lasofoxifene is a selective estrogen receptor modulator, or SERM, in the same chemical class as raloxifene. With its high affinity for estrogen receptors, WELT ONLINE, Buy diclofenac - Jan 17, 2009 Gift pregnancy buy diclofenac raloxifene mechanism icos service miami. Working buy diclofenac need discontinued buy diclofenac diet buy farmacia glycemic Griggs County Courier, Strontium ranelate - Jan 21, 2009 ...at stopping you breaking a bone than treatments like the bisphosphonates (alendronate and risedronate, for example), or raloxifene or teriparatide. guardian.co.uk, What treatments work for fibroids? - Jan 21, 2009 Taking progestogen hormone replacement therapy, a drug called raloxifene (Evista), or tibolone (Livial) at the same time reduces the chances that you'll get guardian.co.uk, Efficacia comparativa dei farmaci nel prevenire le fratture non ... - Feb 2, 2009 Risedronato, raloxifene e alendronato mostrano un’efficacia simile nel prevenire il rischio di fratture non vertebrali. Lo studio di coorte qui presentato Pillole.org, í™”ì?´ìž?, FDA로부터 ‘ë?¼ì†Œí?시펜’ ì™„ì „ ë°˜ì?‘ 통보 - Jan 19, 2009 Lasofoxifeneì?€ raloxifeneê³¼ ë?™ì?¼í•œ 계열ì?˜ ì„ íƒ?ì ? ì—?스트로ì 수용체 ì¡°ì ˆë¬¼ì§ˆ(SERM)ë¡œ ì—?스트로ì 수용체ì—? 매우 친화성ì?´ 높다. 골ì—?는 촉진작용ì?„ ìœ ë°©ì—?는 ê¸¸í• ë©”ë””í?¬ë‰´ìŠ¤, هشاشة العظام لدى الرجال.. الوقاية والعلاج - Jan 10, 2009 ومع ذلك Ù?إن «رالوكسيÙ?ين« raloxifene الذي يعمل على الاستروجين يظل آمنا ÙˆÙ?عالا للنساء بعد سن اليأس. إلا أن كلا الدواءين المذكورين آنÙ?ا ليسا Ù…Ù?يدا للرجال. الشرق الاوسط, ΟστεοπόÏ?ωση: από τη διάγνωση στη θεÏ?απεία - Jan 20, 2009 Οι επιλεκτικοί Ï?υθμιστÎÏ‚ οιστÏ?ογονικών υποδοχÎων (SERMs, Selective estrogen receptor modulator), όπως το raloxifene, δÏ?ουν στο οστό καθυστεÏ?ώντας την ΙατÏ?οnet, Il tumore al seno si può combattere - Jan 17, 2009 ...studi: Retinoidi, Antiossidanti (Vitamina E, Acido ascorbico e Beta-carotene), farmaci anti-infiammatori e sostanze ormonali (Tamoxifene e Raloxifene). Dossier Medicina, Kanserden Korunmanın Kuralları DeÄŸiÅŸiyor - Jan 9, 2009 ...artık bazı kanser türlerinin önlenebilir olduÄŸunu kaydederek, etken maddesi Raloxifene olan bir ilaç ile meme kanserine yakalanma riski yüksek olan Medikal Teknik Dergisi, Characteristics of patients initiating raloxifene compared to ... - Dec 23, 2008 Both raloxifene and bisphosphonates are indicated for the prevention and treatment of postmenopausal osteoporosis, however, these medications have different 7thSpace Interactive (press release), UPMC breast-cancer specialist taking national post - Dec 23, 2008 Dr. Vogel served as the national protocol chairman of the National Cancer Institute's STAR Trial, which studied the drugs Tamoxifen and Raloxifene. Pittsburgh Post Gazette, SABCS: Investigational Osteoporosis Drug May Reduce Breast Cancer Risk - Dec 11, 2008 The significant 85% reduction in relative risk compared with reported reductions of 43% with tamoxifen and 72% with raloxifene (Evista), the researchers MedPage Today, Risks, benefits of cancer-preventing drugs - Dec 1, 2008 In recent years, the Food and Drug Administration has approved two medications -- the cancer drug tamoxifen and the osteoporosis drug raloxifene -- for Daily Camera, Comprehensive Breast Care: An Update for the Menopause Practitioner - Dec 4, 2008 Weigh the relative risks and benefits of the primary chemoprevention options for breast cancer -- including tamoxifen and raloxifene -- when used in Medscape Breast Cancer Prevention: High-Risk Women Face Difficult Decisions - Dec 4, 2008 Another hormonal medicine, raloxifene (Evista), is able to lower breast cancer risk with about as much success as Tamoxifen, but it causes some of the same Gather.com, Update on JAMA-EXPRESS Rapid Review and Publication - Dec 23, 2008 Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene Journal of American Medical Association (subscription), SABCS: Breast Density May Reveal Tamoxifen Benefit for Chemoprevention - Dec 15, 2008 ...the breast density effect is only for tamoxifen or could predict efficacy of other preventive strategies, such as raloxifene (Evista), Dr. Cuzick said. MedPage Today, Kanserden Korunmanın Formülü - Dec 24, 2008 ...artık bazı kanser türlerinin önlenebilir olduÄŸunu kaydederek, etken maddesi Raloxifene olan bir ilaç ile meme kanserine yakalanma riski yüksek olan Taka, Gıdaları ilaç haline getirmeyin - Dec 21, 2008 California Ãœniversitesi öğretim üyesi Prof Dr. Frank Meyskens de artık bazı kanser türlerinin önlenebilir olduÄŸunu kaydederek, etken maddesi Raloxifene olan NTVMSNBC, Brand Names/Synonyms: Raloxifene is also known by the following brand names and/or synonymsCCRIS 7129; CHEMBANK1694; Evista; Keoxifene; RAL; Raloxifene; Raloxifene Hcl; Raloxifene Hydrochloride; Raloxifeno [Spanish]; Raloxifenum [Latin] Drug Category: Raloxifene is categorized under the following by the FDA: Antihypocalcemic Agents; Osteoporosis Prophylactic; Selective Estrogen Receptor Modulators; Estrogen Antagonists; ATC:G03XC01 Dosage Forms: Tablet Absorption: Approximately 60% of an oral dose is absorbed, but presystemic glucuronide conjugation is extensive. Absolute bioavailability of raloxifene is 2.0% Interactions: Interactions for Raloxifene: Cholestyramine: Cholestyramine causes a 60% reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with EVISTA. Warfarin: The coadministration of EVISTA and warfarin has not been assessed under chronic conditions. However, 10% decreases in prothrombin time have been observed in single-dose studies. If EVISTA is given concurrently with warfarin, prothrombin time should be monitored. Other Highly Protein-Bound Drugs: Raloxifene is more than 95% bound to plasma proteins. In vitro, raloxifene did not affect the binding of warfarin, phenytoin, or tamoxifen. Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. See also CLINICAL PHARMACOLOGY, Drug-Drug Interactions Chemical IUPAC Name: [6-hydroxy-2-(4-hydroxyphenyl)-benzothiophen-3-yl]-[4-[2-(1-piperidyl)ethoxy]phenyl]-methanone : |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines mongabay.com
COPYRIGHT 2007 MONGABAY.COM |